A hybrid Ornstein-Uhlenbeck-Branching framework unifies microbial and pediatric tumor evolution

Ornstein-Uhlenbeck-Branching混合框架统一了微生物和儿童肿瘤的演化

阅读:1

Abstract

INTRODUCTION: Pediatric tumors can relapse despite low mutation burdens, suggesting hybrid evolutionary dynamics shaped by stochastic variability and stabilizing forces. We develop a hybrid Ornstein-Uhlenbeck (OU)-Branching framework that couples mean-reverting stochastic trait dynamics with demographic birth-death processes to model lineage diversification under effective stabilizing constraints. METHODS: Using Escherichia coli long-term evolution experiment (LTEE) lineages (WT, priA, recG), we parameterized the equilibrium mean (μ), mean-reversion strength (θ), and diffusion scale (σ) on the log10 mutation-frequency axis via replicate-grouped likelihood inference. We performed forward simulations for predictive envelopes, uncertainty quantification, phase-plane dynamics, and OU-Branching lineage networks. We also ran illustrative in silico therapy simulations under fixed OU parameters with exposure-modulated birth/death rates. RESULTS: The fitted model recapitulated lineage-specific mutation dynamics and branching architectures. priA exhibited elevated stochastic dispersion and drift-prone behavior consistent with a high-plasticity regime, whereas recG showed constrained diversification and increased lineage turnover consistent with a collapse-prone regime. Illustrative therapy simulations generated oscillatory trait trajectories, suppression-rebound population dynamics, clonal pruning, and extinction-versus-persistence regimes. DISCUSSION: Although Y is directly observed as log10 mutation frequency in LTEE, in tumors Y can represent a longitudinally measurable phenotypic state (e.g., drug-tolerance scores from single-cell data, MRD/VAF-derived burden proxies, or pathway activity states). The balance between stabilizing strength (θ) and stochastic variability (σ) provides a quantitative axis governing plasticity and persistence, motivating future calibration to clinical longitudinal data for evolution-aware, patient-specific modeling.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。